Feasibility of a Video-oculography in Patients With Huntington's Disease VOG-HD Study

Huntington Disease Clinical Trial

— VOG-HD  

Official title:

Feasibility of a Video-oculography in Patients With Huntington's Disease VOG-HD Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02563418
• Other study ID #: AOI 2013 - 11
• Status: Recruiting
• Phase: N/A
• First received: September 8, 2015
• Last updated: September 29, 2015
• Start date: May 2014

Study information

• Verified date: September 2015
• Source: University Hospital, Angers
• Contact: Sophie Hue
• Phone: 33 (0)241353800
• Email: sophie.hue[@]chu-angers.fr
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to know the limits of feasibility of a reliable oculomotor record for patient with Huntington's disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. primary completion date: May 2017
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Corrected visual acuity >1/10

• Aged over 18 years

• Patient with the mutation that is to say the presence of an abnormal number of trinuclide: CAG> 38 in the first exon of the huntingtin gene.

• Total Functional Capacity Scale (CFT) = 3

Exclusion Criteria:

• Patients or trustworthy person who have not given their written consent, informed and signed.

• Patients are not affiliated or who are not entitled to Social Security

• Private patients of liberty by administrative or judicial decision, or patients supervision

• Associated disease with neurological repercussions

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Huntington Disease

Intervention

Device:
• Eye-tracking

Locations

Country	Name	City	State
France	Centre Hospitalier Universitaire	Angers

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Angers

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	saccadic measures with the eye tracker	one measure in the evening and one in the afternoon	1 day	No